Antineoplastic drug-induced nausea and vomiting in pediatric onco-hematology : 2022: Guidelines from the supportive care committee of the French Society of Childhood Cancer (SFCE)
Copyright © 2022 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved..
Nausea and vomiting induced by cancer treatment (CINV) remain one of the most common and feared side effects in children despite the use of new drugs to prevent them. The existing recommendations for the prophylaxis and treatment of CINV are based on adult patients in Anglo-Saxon societies. Based on a recent review of the literature, we focused on specific pediatric issues in order to offer recommendations validated by the supportive care committee of the French society for childhood cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:109 |
|---|---|
| Enthalten in: |
Bulletin du cancer - 109(2022), 11 vom: 04. Nov., Seite 1144-1153 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Nausées-vomissements induits par les traitements anticancéreux (NVITAC) en onco-hématologie pédiatrique : recommandations 2022 du Comité soins de support de la SFCE |
|---|
| Beteiligte Personen: |
Thouvenin-Doulet, Sandrine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiemetics |
|---|
| Anmerkungen: |
Date Completed 25.10.2022 Date Revised 29.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bulcan.2022.08.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347358756 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347358756 | ||
| 003 | DE-627 | ||
| 005 | 20231226033632.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.bulcan.2022.08.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1157.xml |
| 035 | |a (DE-627)NLM347358756 | ||
| 035 | |a (NLM)36220696 | ||
| 035 | |a (PII)S0007-4551(22)00338-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Thouvenin-Doulet, Sandrine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antineoplastic drug-induced nausea and vomiting in pediatric onco-hematology |b 2022: Guidelines from the supportive care committee of the French Society of Childhood Cancer (SFCE) |
| 246 | 3 | 3 | |a Nausées-vomissements induits par les traitements anticancéreux (NVITAC) en onco-hématologie pédiatrique : recommandations 2022 du Comité soins de support de la SFCE |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.10.2022 | ||
| 500 | |a Date Revised 29.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Nausea and vomiting induced by cancer treatment (CINV) remain one of the most common and feared side effects in children despite the use of new drugs to prevent them. The existing recommendations for the prophylaxis and treatment of CINV are based on adult patients in Anglo-Saxon societies. Based on a recent review of the literature, we focused on specific pediatric issues in order to offer recommendations validated by the supportive care committee of the French society for childhood cancer | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Childhood cancer | |
| 650 | 4 | |a Guidelines | |
| 650 | 4 | |a Nausea | |
| 650 | 4 | |a Nausées | |
| 650 | 4 | |a Oncologie | |
| 650 | 4 | |a Pédiatrie | |
| 650 | 4 | |a Recommandations | |
| 650 | 4 | |a Vomissements | |
| 650 | 4 | |a Vomiting | |
| 650 | 7 | |a Antiemetics |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Mouffak, Samia |e verfasserin |4 aut | |
| 700 | 1 | |a Bertrand, Amandine |e verfasserin |4 aut | |
| 700 | 1 | |a Cardine, Aude Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Letort-Bertrand, Maïna |e verfasserin |4 aut | |
| 700 | 1 | |a Levy, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Wiart-Monger, Virginie |e verfasserin |4 aut | |
| 700 | 1 | |a Lervat, Cyril |e verfasserin |4 aut | |
| 700 | 1 | |a Poirée, Marilyne |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin du cancer |d 1966 |g 109(2022), 11 vom: 04. Nov., Seite 1144-1153 |w (DE-627)NLM000155853 |x 1769-6917 |7 nnns |
| 773 | 1 | 8 | |g volume:109 |g year:2022 |g number:11 |g day:04 |g month:11 |g pages:1144-1153 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bulcan.2022.08.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 109 |j 2022 |e 11 |b 04 |c 11 |h 1144-1153 | ||